Trial · NCT00934544
Participant flow27
How many started, completed or left each group, period by period.
1 to 20 of 27
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Primary Endpoint Analysis (Interim) | STARTED | Ruxolitinib | 146 | |
| Primary Endpoint Analysis (Interim) | STARTED | Best Available Therapy (BAT) | 73 | |
| Primary Endpoint Analysis (Interim) | STARTED | Ruxolitinib After BAT (Cross-over) | 0 | |
| Primary Endpoint Analysis (Interim) | COMPLETED | Ruxolitinib | 91 | |
| Primary Endpoint Analysis (Interim) | COMPLETED | Best Available Therapy (BAT) | 31 | |
| Primary Endpoint Analysis (Interim) | COMPLETED | Ruxolitinib After BAT (Cross-over) | 0 | |
| Primary Endpoint Analysis (Interim) | NOT COMPLETED | Ruxolitinib | 55 | |
| Primary Endpoint Analysis (Interim) | NOT COMPLETED | Best Available Therapy (BAT) | 42 | |
| Primary Endpoint Analysis (Interim) | NOT COMPLETED | Ruxolitinib After BAT (Cross-over) | 0 | |
| Overall Disposition at 5 Year Follow-up | STARTED | Ruxolitinib | 146 | |
| Overall Disposition at 5 Year Follow-up | STARTED | Best Available Therapy (BAT) | 28 | |
| Overall Disposition at 5 Year Follow-up | STARTED | Ruxolitinib After BAT (Cross-over) | 45 | |
| Overall Disposition at 5 Year Follow-up | Crossed Over After Qualifying Event | Ruxolitinib | 0 | |
| Overall Disposition at 5 Year Follow-up | Crossed Over After Qualifying Event | Best Available Therapy (BAT) | 0 | |
| Overall Disposition at 5 Year Follow-up | Crossed Over After Qualifying Event | Ruxolitinib After BAT (Cross-over) | 27 | |
| Overall Disposition at 5 Year Follow-up | Crossed Over After AMEND 5 | Ruxolitinib | 0 | |
| Overall Disposition at 5 Year Follow-up | Crossed Over After AMEND 5 | Best Available Therapy (BAT) | 0 | |
| Overall Disposition at 5 Year Follow-up | Crossed Over After AMEND 5 | Ruxolitinib After BAT (Cross-over) | 12 | |
| Overall Disposition at 5 Year Follow-up | Crossed Over: Other | Ruxolitinib | 0 | |
| Overall Disposition at 5 Year Follow-up | Crossed Over: Other | Best Available Therapy (BAT) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00934544/flow